323 related articles for article (PubMed ID: 28482858)
41. Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience.
Bardazzi F; Magnano M; Campanati A; Loconsole F; Carpentieri A; Potenza C; Bernardini N; Di Lernia V; Carrera C; Raone B; Patrizi A; Loi C
Acta Derm Venereol; 2017 Aug; 97(8):989-990. PubMed ID: 28512671
[No Abstract] [Full Text] [Related]
42. Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice.
Atalay S; van der Schoot LS; Vandermaesen L; van Vugt LJ; Eilander M; van den Reek JMPA; de Jong EMGJ
Acta Derm Venereol; 2021 May; 101(5):adv00463. PubMed ID: 33903920
[TBL] [Abstract][Full Text] [Related]
43. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
Wu JJ; Feldman SR; Rastogi S; Menges B; Lingohr-Smith M; Lin J
J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
[TBL] [Abstract][Full Text] [Related]
44. Comparative efficacy of biologics in psoriasis: a review.
Kim IH; West CE; Kwatra SG; Feldman SR; O'Neill JL
Am J Clin Dermatol; 2012 Dec; 13(6):365-74. PubMed ID: 22967166
[TBL] [Abstract][Full Text] [Related]
45. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
Kokolakis G; Warren RB; Strober B; Blauvelt A; Puig L; Morita A; Gooderham M; Körber A; Vanvoorden V; Wang M; de Cuyper D; Madden C; Nunez Gomez N; Lebwohl M
Br J Dermatol; 2023 Feb; 188(3):330-340. PubMed ID: 36751950
[TBL] [Abstract][Full Text] [Related]
46. Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan.
Chen YC; Huang YT; Yang CC; Lai EC; Liu CH; Hsu CK; Wong TW; Chao SC; Sheu HM; Lee CN
PLoS One; 2020; 15(12):e0244620. PubMed ID: 33373425
[TBL] [Abstract][Full Text] [Related]
47. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
[TBL] [Abstract][Full Text] [Related]
48. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
[TBL] [Abstract][Full Text] [Related]
49. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
50. Patient Preference for Dosing Frequency Based on Prior Biologic Experience.
Zhang M; Carter C; Olson WH; Johnson MP; Brennem SK; Lee S; Farahi K
J Drugs Dermatol; 2017 Mar; 16(3):220-226. PubMed ID: 28301617
[TBL] [Abstract][Full Text] [Related]
51. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
[TBL] [Abstract][Full Text] [Related]
52. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
[TBL] [Abstract][Full Text] [Related]
53. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
[TBL] [Abstract][Full Text] [Related]
54. Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response.
Signorovitch JE; Betts KA; Yan YS; LeReun C; Sundaram M; Wu EQ; Mulani P
Br J Dermatol; 2015 Feb; 172(2):504-12. PubMed ID: 25288183
[TBL] [Abstract][Full Text] [Related]
55. Dose increase beyond labelled dose of biologics is associated with incremental pharmacy costs: results from a real-world study in the UK.
Bewley A; Miglio C; Tian H; Gilloteau I; Whitehead J; Hermans R
J Dermatolog Treat; 2019 Jun; 30(4):376-382. PubMed ID: 30256686
[No Abstract] [Full Text] [Related]
56. Efficacy of biologic therapies in psoriasis vulgaris.
Mala R; Fida M; Jorgaqi E; Vasili E
Dermatol Ther; 2019 Jul; 32(4):e12936. PubMed ID: 30983095
[TBL] [Abstract][Full Text] [Related]
57. Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population.
Norris D; Photiou L; Tacey M; Dolianitis C; Varigos G; Foley P; Baker C
J Dermatolog Treat; 2017 Dec; 28(8):731-736. PubMed ID: 28489479
[TBL] [Abstract][Full Text] [Related]
58. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.
Norlin JM; Calara PS; Persson U; Schmitt-Egenolf M
J Dermatolog Treat; 2017 Sep; 28(6):500-504. PubMed ID: 28132580
[TBL] [Abstract][Full Text] [Related]
59. Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review.
Michielsens CAJ; van Muijen ME; Verhoef LM; van den Reek JMPA; de Jong EMGJ
Drugs; 2021 Feb; 81(3):349-366. PubMed ID: 33453052
[TBL] [Abstract][Full Text] [Related]
60. Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.
Wang SH; Chi CC; Hu S
Int J Dermatol; 2014 Sep; 53(9):1151-6. PubMed ID: 24738910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]